LOW-VOLUME · HOSP-HEAVY
octreotide Side Effects
octreotide (also sold as Sandostatin) is a LOW-VOLUME FAERS extract #390 of 524 by FAERS report count. Still opens on HOSP-HEAVY: 41.4% mention hospitalization (2,164 reports).
Data updated 2026-05-15
- 5,230
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
octreotide: 41.4% mention hospitalization (2,164 reports). Death stamp DEATH-HEAVY; volume band LOW-VOLUME #390 of 524 by FAERS report count.
Thinner FAERS extract for octreotide (Sandostatin) (5,230 reports #390 of 524 by FAERS report count). 41.4% mention hospitalization (2,164 reports). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
DIARRHOEA leads 526 of 5,230 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (1,327 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (870 reports, 16.6%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 369 |
| DIARRHOEA | 74 |
| MALIGNANT NEOPLASM PROGRESSION | 66 |
| SEPSIS | 47 |
| ASTHENIA | 46 |
| ACUTE KIDNEY INJURY | 42 |
| NAUSEA | 41 |
| DYSPNOEA | 40 |
| VOMITING | 37 |
| FATIGUE | 36 |
| ABDOMINAL PAIN | 35 |
| DECREASED APPETITE | 34 |
| HYPOGLYCAEMIA | 34 |
| WEIGHT DECREASED | 33 |
| DISEASE PROGRESSION | 32 |
| PNEUMONIA | 32 |
| CONDITION AGGRAVATED | 31 |
| HYPOTENSION | 31 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (2,164, 41.4% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| DIARRHOEA | 256 |
| NAUSEA | 160 |
| FATIGUE | 143 |
| VOMITING | 119 |
| ABDOMINAL PAIN | 114 |
| DYSPNOEA | 108 |
| ASTHENIA | 101 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 101 |
| MALIGNANT NEOPLASM PROGRESSION | 99 |
| PYREXIA | 99 |
| DEATH | 96 |
| ACUTE KIDNEY INJURY | 94 |
| WEIGHT DECREASED | 93 |
| HOSPITALISATION | 87 |
| FALL | 83 |
| PAIN | 83 |
| DECREASED APPETITE | 82 |
| DEHYDRATION | 77 |
How to read octreotide FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 5,230 voluntary reports linked to octreotide (Sandostatin), 2004-2025. Death is listed on 870 (16.6%). Hospitalization appears on 2,164 (41.4%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.
Read with octreotide
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 5,225 FAERS cases (Δ 5 lighter vs octreotide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 5,207 FAERS cases (Δ 23 lighter vs octreotide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 5,119 FAERS cases (Δ 111 lighter vs octreotide); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 5,342 FAERS cases (Δ 112 heavier vs octreotide); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 45.5 pp vs octreotide's DEATH-HEAVY): CASELOAD · HOSP-MID.
octreotide stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.